Keros Therapeutics, Inc.
KROS
$10.10
-$0.56-5.25%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -4.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -4.68% | |||
| Cost of Revenue | 38.73% | -9.63% | |||
| Gross Profit | -41.96% | 9.74% | |||
| SG&A Expenses | -15.19% | -13.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.88% | -11.20% | |||
| Operating Income | -19.55% | 11.29% | |||
| Income Before Tax | -21.10% | 5.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.10% | -1.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.10% | -1.05% | |||
| EBIT | -19.55% | 11.29% | |||
| EBITDA | -19.87% | 11.46% | |||
| EPS Basic | -20.06% | -40.01% | |||
| Normalized Basic EPS | -20.06% | -32.05% | |||
| EPS Diluted | -19.83% | -40.27% | |||
| Normalized Diluted EPS | -20.06% | -32.05% | |||
| Average Basic Shares Outstanding | 0.87% | -27.83% | |||
| Average Diluted Shares Outstanding | 0.87% | -27.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||